Promotes Fat Loss

Fat reduction is the major benefit of tesamorelin. In fact, the US Food and Drug Administration approved tesamorelin last November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Several lines of evidence clearly support this fat burning effect:
1. In HIV patients with central fat accumulation, subcutaneous injection of tesamorelin at a dose of 2 mg was generally well tolerated and resulted in sustained decrease in visceral adipose tissue (active component of total body fat). [1]
2. A 2010 study published in the Journal of Acquired Immune Deficiency Syndromes found that tesamorelin reduced visceral fat (body fat stored within the abdominal cavity) by approximately 18% and improved body image distress in HIV-infected patients with central fat accumulation.[2]
3. A 2011 study published in HIV/AIDS – Research and Palliative Care has shown that tesamorelin is safe and effective in reducing central fat accumulation among HIV-infected patients. [3]
4. In HIV patients with abdominal adiposity, tesamorelin reduced visceral adipose tissue by increasing adiponectin, a protein that breaks down fat. [4]
5. In patients with HIV-related lipodystrophy, 52 weeks of tesamorelin treatment reduced abdominal fat. [5]
6. A 2015 study published in PLoS One Journal found that patients with baseline metabolic syndrome, elevated triglyceride levels, or white race were most likely to experience reductions in visceral adipose tissue following 6 months of tesamorelin treatment. [6]
7. In HIV-infected patients with excess abdominal fat, treatment with tesamorelin reduced visceral adipose tissue and maintained the reduction for up to 52 weeks. [7]
8. In HIV-infected patients with abdominal fat accumulation, daily tesamorelin treatment for 26 weeks decreased visceral fat by 15.2% compared to placebo. [8]
9. In HIV-infected patients receiving tesamorelin, reduction in visceral adipose tissue is accompanied by improvement in metabolic profile. [9]